Company profile
Bright Minds Biosciences Inc.
DRUG · Nasdaq (also CSE) (The 'Pty Ltd' entity is the Australian operating subsidiary of Bright Minds Biosciences Inc., a CNS biotech (selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other disorders) publicly traded as DRUG on both Nasdaq and the CSE; the parent closed a US$175M public offering in January 2026. Not currently on our roster. Sources: https://clinicaltrials.gov/study/NCT06401538 ; https://www.sec.gov/Archives/edgar/data/1827401/000106299326000151/exhibit99-1.htm Entity resolved by asset-pipeline-v2.)
Share price · DRUG
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Serotonin 5-HT2C receptor (biased agonist)Small molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.